Select Language
Free Registration

Featured Articles

Coming Soon, The RSV VaccinesHot

Feb 3, 2023

Hot Coming Soon, The RSV Vaccines

Respiratory syncytial virus (RSV) is a significant contributor to infant mortality with limited prevention and treatment options. The fusion glycoprotein of RSV is thought as an ideal target for vaccine R&D, which exists in pre- and post-fusion forms. Due to their different performance in inducing n

Read more
Evaluating Inhaled Aerosol Vaccines: No-needle COVID-19 Protection?Hot

Dec 26, 2022

Hot Evaluating Inhaled Aerosol Vaccines: No-needle COVID-19 Protection?

The COVID-19 epidemic has now entered its third year with its effects still being felt across the world. In many countries, there have been an alarming trend of waning vaccine efficacy paired with the emergence of variants with stronger immune escape and transmission ability. This consistent challen

Read more
COVID-19 vaccine development and its implications for the future of vaccinesHot

Nov 8, 2022

Hot COVID-19 vaccine development and its implications for the future of vaccines

COVID-19 vaccine development against the pandemic, biopharmaceutical reagents and services support infectious diseases research

Read more

Explore by Subtopics

Coming Soon, The RSV VaccinesHot
Feb 3, 2023|Vaccines

Coming Soon, The RSV Vaccines

Evaluating Inhaled Aerosol Vaccines: No-needle COVID-19 Protection?Hot
Dec 26, 2022|Vaccines

Evaluating Inhaled Aerosol Vaccines: No‑needle COVID‑19 Protection?

COVID-19 vaccine development and its implications for the future of vaccinesHot
Nov 8, 2022|Vaccines

COVID‑19 vaccine development and its implications for the future of vaccines

Viruses and Vaccines: Two Sides of the Same Coin
Oct 19, 2022|Vaccines

Viruses and Vaccines: Two Sides of the Same Coin

Variant Boosters, Bivalent and Polyvalent Vaccines… Who’s Going to Break the Stalemate with COVID-19?
Aug 9, 2022|Vaccines

Variant Boosters, Bivalent and Polyvalent Vaccines… Who’s Going to Break the Stalemate with COVID‑19?

ACROBiosystems announces the release of their latest BA.2.75 antigen products
Aug 5, 2022|Vaccines

ACROBiosystems announces the release of their latest BA.2.75 antigen products

BA.2.75: After BA.5, the next generation of the most virulent strain may have appeared
Jul 29, 2022|Vaccines

BA.2.75: After BA.5, the next generation of the most virulent strain may have appeared

Omicron recombinants and new variants: Who is the next master for immune escape?
May 30, 2022|Vaccines

Omicron recombinants and new variants: Who is the next master for immune escape?

Explore More Topics

Cell and Gene Therapy

Cell and Gene Therapy

Antibody-Drug Conjugates

Antibody-Drug Conjugates

CMC Manufacturing & QC

CMC Manufacturing & QC

Bispecific Antibodies

Bispecific Antibodies

Disease Areas

Disease Areas

Research & Innovation

Research & Innovation

Biomarker-Driven Bioanalysis

Biomarker-Driven Bioanalysis

Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland